Because we observed fewer SMA+ cells in Mock tumors than VEGFR2-Fc–expressing tumors in both models, these cells, during chronic exposure to anti-VEGF therapy, might be recruited from blood into the tumor microenvironment by secreted factors or might be differentiated from other cell types in the tumor microenvironment. The gene discussed is KDR; the disease is neoplasm.